Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 7,400 shares, a decline of 23.7% from the October 15th total of 9,700 shares. Based on an average daily trading volume, of 10,200 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.3% of the company’s shares are short sold.

Traws Pharma Stock Performance

TRAW stock traded down $0.59 during trading on Friday, reaching $4.99. 5,965 shares of the stock were exchanged, compared to its average volume of 5,875. Traws Pharma has a twelve month low of $4.44 and a twelve month high of $27.50. The company has a market cap of $9.13 million, a P/E ratio of -0.04 and a beta of 1.41.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Thursday, August 15th. The company reported ($4.87) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million during the quarter. Traws Pharma had a negative net margin of 60,641.14% and a negative return on equity of 144.95%. Equities analysts predict that Traws Pharma will post -146 earnings per share for the current year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.